Mode
Text Size
Log in / Sign up
Phase 2 N=52 Diagnostic

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Biochemical Recurrence of Malignant Neoplasm of Prostate

Enrolled (actual)
52
Serious AEs
1.9%
Results posted
Oct 2024
Primary outcome: Primary: Safety and Tolerability — 10; 8; 2; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
64Cu-SAR-bisPSMA (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
Clarity Pharmaceuticals Ltd
Primary completion
Aug 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety and Tolerability
10; 8; 2; 0; 1; 1
PRIMARY
Participant-level Correct Detection Rate (CDR)- Day 0
26.2; 23.8; 19.0
PRIMARY
Participant-level CDR- Day 1
33.3; 33.3; 26.2
PRIMARY
Region-level Positive Predictive Value (PPV)- Day 0
41.2; 44.8; 39.1
PRIMARY
Region-level PPV- Day 1
41.5; 32.7; 43.3
SECONDARY
Biodistribution of 64Cu-SAR-bisPSMA- SUVmean
9.898; 15.818; 8.990; 14.678; 6.635; 14.729
SECONDARY
Biodistribution of 64Cu-SAR-bisPSMA- SUVmax
13.973; 22.198; 13.914; 22.789; 13.924; 33.363
SECONDARY
Biodistribution of 64Cu-SAR-bisPSMA- SUVr
23.233; 118.051; 23.476; 121.306; 25.448; 181.673
SECONDARY
Participant-level PPV
44.0; 45.2; 43.5; 40.0; 42.1; 47.8
SECONDARY
Participant-level Detection Rate (DR)
58.0; 74.0; 56.0; 80.0; 44.0; 58.0
SECONDARY
Participant-level False Positive Rate (FPR)
53.8; 54.8; 54.2; 60.0; 57.9; 50.0
SECONDARY
Region-level FPR
58.8; 57.1; 55.2; 67.3; 60.9; 56.7
SECONDARY
Participant-level Discrepant PET Negativity Rate
14.3; 21.4; 42.9
SECONDARY
Participant-level True Negative Rate (TNR)
50.0; 39.3; 53.6; 25.0; 60.7; 57.1
SECONDARY
Region-level TNR
88.7; 86.4; 91.0; 80.1; 92.1; 90.4

Summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age.
  • Signed informed consent.
  • Life expectancy ≥ 12 weeks as determined by the Investigator.
  • Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
  • Suspected recurrence of prostate cancer (PC) based on rising Prostate-specific antigen (PSA) after definitive therapy on the basis of:
  • Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per American Urological Association recommendation) or
  • Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per American Society for Therapeutic Radiology and Oncology-Phoenix consensus definition).
  • Negative or equivocal findings for PC on conventional imaging performed as part of standard of care workup within 60 days prior to Day 0.
  • The Eastern Cooperative Oncology performance status 0-2.
  • Adequate recovery from acute toxic effects of any prior therapy.
  • Estimated Glomerular Filtration Rate of 30 mL/min or higher.
  • Adequate liver function.
  • For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.

Exclusion Criteria

  • Participants who received other investigational agents within 28 days prior to Day 0.
  • Participants administered any high energy (>300 kiloelectronvolts (keV)) gamma-emitting radioisotope within 5 physical half-lives prior to Day 0.
  • Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for PC.
  • Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
  • Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05249127). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search